Norris Medicines Ltd
Norris Medicines Ltd (NORRIS) last traded at ₹15.5, a market capitalisation of ₹15.5 crore. Over the past 52 weeks the stock has ranged between ₹12 and ₹19.6. Norris Medicines Ltd last reported results for the quarter ended Jun 2026, with sales of ₹0.92 crore and net profit of ₹-0.4 crore. Figures are as of 25 Aug 2026 and are not real time.
Norris Medicines Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Norris Medicines Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹0.92 cr, down 37.0% from ₹1.46 cr a year earlier. Net profit was ₹-0.4 cr, down 29.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1.27 | 1.11 | 2.72 | 1.46 | 2 | 3.27 | 1.41 | 0.92 |
| Expenses | 1.42 | 1.14 | 2.65 | 1.56 | 2.49 | 2.32 | 1.11 | 1.2 |
| Operating profit | -0.15 | -0.03 | 0.07 | -0.1 | -0.49 | 0.95 | 0.3 | -0.28 |
| OPM % | -11.81% | -2.70% | 2.57% | -6.85% | -24.50% | 29.05% | 21.28% | -30.43% |
| Other income | 0 | 0 | 0.05 | 0.02 | 0 | 0 | 0.02 | 0 |
| Interest | 0.08 | 0.12 | 0.15 | 0.11 | 0.11 | 0.13 | 0.15 | 0 |
| Depreciation | 0.13 | 0.13 | 0.14 | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 |
| Profit before tax | -0.36 | -0.28 | -0.17 | -0.31 | -0.72 | 0.7 | 0.05 | -0.39 |
| Tax % | 0.00% | 0.00% | 35.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -0.36 | -0.28 | -0.23 | -0.31 | -0.72 | 0.7 | 0.05 | -0.4 |
| EPS (₹) | -0.36 | -0.28 | -0.23 | -0.31 | -0.72 | 0.70 | 0.05 | -0.40 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Norris Medicines Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 12.25 | 9.44 | 8.36 | 5.64 | 5.82 | 8.13 | 7.6 |
| Operating profit | -1.75 | -0.08 | 0.93 | -0.17 | -0.26 | 0.66 | 0.48 |
| OPM % | -14.29% | -0.85% | 11.12% | -3.01% | -4.47% | 8.12% | 6.32% |
| Net profit | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -0.28 | -0.37 |
| EPS (₹) | -4.96 | -3.26 | -1.75 | -1.19 | -1.24 | -0.28 | -0.37 |
TTM is the trailing twelve months to the most recent quarter.
Norris Medicines Ltd growth and returns
- 10 Years
- -8%
- 5 Years
- -8%
- 3 Years
- -1%
- TTM
- 16%
- 10 Years
- %
- 5 Years
- 14%
- 3 Years
- 23%
- TTM
- 69%
- 10 Years
- %
- 5 Years
- 14%
- 3 Years
- 10%
- 1 Year
- -1%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Norris Medicines Ltd shareholding pattern
Promoters held 34.01% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.07%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 34.01% | 34.00% | 34.00% | 34.00% | 34.00% | 34.00% | 34.01% | 34.01% |
| DIIs | 0.07% | 0.07% | 0.07% | 0.07% | 0.07% | 0.07% | 0.07% | 0.07% |
| Public | 65.91% | 65.92% | 65.93% | 65.93% | 65.92% | 65.92% | 65.90% | 65.90% |
| No. of shareholders | 25,498 | 25,659 | 25,815 | 25,950 | 25,895 | 25,791 | 25,777 | 25,777 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Norris Medicines Ltd corporate filings
- Board Meeting held on August 14, 2026 for the quarter ended June 30, 2026.Board Meetinghigh impact
Cruxal's analysis: Norris Medicines Limited reported a weak financial performance for the quarter ended June…
Read the full analysis - Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Unaudited Financial Results ....Board Meetinglow impact
Cruxal's analysis: Norris Medicines Limited has issued a formal intimation regarding a Board Meeting…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Norris Medicines Ltd
Cruxal reads every Norris Medicines Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.